W.H.P.M. Inc. and Healgen Scientific Agree to Preliminary Injunction in Patent Infringement Lawsuit

Share Article

The preliminary injunction prohibits Healgen’s manufacture, use or sale of certain products marketed under the Swabscreen brand or any other label.

We have invested significant time and resources into developing our oral fluid drug tests and collection systems. The agreement announced today recognizes that investment.

W.H.P.M. Inc. (“W.H.P.M.”), a leading developer and manufacturer of rapid drugs of abuse and medical diagnostics devices, announced today that the company and Healgen Scientific LLC (“Healgen”) have agreed to a preliminary injunction in a patent infringement lawsuit brought by W.H.P.M. The lawsuit, filed in the U.S. District Court for the Southern District of Texas (Case 4:18-cv-02302), Houston Division alleged infringement of U.S. Patent No. 7,927,562 (“'562 Patent”), titled “Collection and Assay Device for Biological Fluid.”

Under the agreement dated May 3, 2019, W.H.P.M. (plaintiff) and Healgen (defendant), mutually agree to the issuance of a preliminary injunction, with the Court finding WHPM entitled to the following relief:

"IT IS THEREFORE ORDERED, ADJUDGED AND DECREED that Defendant Healgen, and any of its affiliates, subsidiaries, suppliers, parent corporations, officers, directors, employees, agents, representatives, licensees, successors, assigns, and all those acting for any of them and/or on any of their behalf, or in active concert or participating with any of them directly or indirectly are hereby enjoined from and commanded to cease and desist from the following:

"Making, using, selling and/or offering for sale in the United States, and/or importing into the United States, products alleged as within the scope of United States Patent No. 7,927,562 (the " '562 Patent"), entitled "Collection and Assay Device for Biological Fluid", namely, the following Healgen devices SWABSCREEN devices manufactured, distributed, sold or offered for sale under any other name or label:


"IT IS FURTHER ORDERED, ADJUDGED, AND DECREED that this Agreed Order of Preliminary Injunction shall remain in effect until further order of this Court."

“W.H.P.M. is pleased to announce an agreement on a preliminary injunction in this lawsuit,” says Dr. John Wan, founder and President of W.H.P.M., Inc. “We have invested significant time and resources into developing our oral fluid drug tests and collection systems. The agreement announced today recognizes that investment.”

About W.H.P.M., Inc.
W.H.P.M., Inc., established in 1993, is headquartered in Irwindale, Calif. The company is a global leader in the research, development, and deployment of the most advanced and innovative one-step membrane tests and medical diagnostics devices on the market today. W.H.P.M. offers customers a variety of fast-turnaround services for rapid diagnostics, including OEM production, customized assembly, and private labeling. It assists companies in rapidly producing a wide array of products by utilizing its extensive experience in advanced bio-technology and design/manufacturing systems. Learn more at whpm.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Aaron Wangen
Visit website


W.H.P.M. logo image